Jump Financial, LLC Ascendis Pharma A/S Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $938,352 - $1.27 Million	-8,304 Closed	0 $0
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $170,224 - $216,060	-1,406 Reduced 14.48%	8,304 $1.13 Million
Q1 2024 May 13, 2024	SELL	$123.45 - $159.4 $448,864 - $579,578	-3,636 Reduced 27.24%	9,710 $1.47 Million
Q4 2023 Oct 21, 2024	BUY	$86.1 - $127.36 $942,450 - $1.39 Million	10,946 Added 456.08%	13,346 $1.68 Million
Q4 2023 Feb 07, 2024	BUY	$86.1 - $127.36 $1.15 Million - $1.7 Million	13,346 New	13,346 $1.68 Million
Q2 2023 Oct 21, 2024	SELL	$69.96 - $97.84 $413,043 - $577,647	-5,904 Reduced 71.1%	2,400 $214,000
Q2 2023 Aug 07, 2023	BUY	$69.96 - $97.84 $167,903 - $234,816	2,400 New	2,400 $214,000
Q2 2022 Aug 09, 2022	BUY	$78.08 - $117.61 $3.12 Million - $4.7 Million	39,938 New	39,938 $3.71 Million
Q4 2021 Feb 10, 2022	SELL	$127.1 - $169.66 $216,070 - $288,422	-1,700 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$112.67 - $176.92 $191,539 - $300,764	1,700 New	1,700 $271,000

243

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $6.84B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.